The study, published in Ocular Oncology and Pathology, saw the use of the company's DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq panels.

Out of 105 tumors studied, DecisionDx-UMSeq achieved a positive percent agreement of 100% for detection of both single-nucleotide variants and insertions/deletions (INDELs), with a technical positive predictive value of 98.8% and 100%, respectively.

The company said combining the three technologies showed the highest accuracy for sample analysis.

Castle Biosciences completes Cernostics acquistion
Castle Biosciences has completed its purchase of Cernostics for $30 million. The company will pay up to $50 million more if Cernostics fulfills...

Genomic tests for melanoma in the spotlight
Appropriate use criteria for three gene expression profiling tests used in the management of suspicious pigmented/melanocytic lesions and biopsy-proven...

Castle Biosciences moves ahead with skin cancer test
Castle Biosciences is moving forward with the development of a prognostic gene expression profiling test for cutaneous squamous cell carcinoma. Researchers...